Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human growth hormone for AIDS-associated wasting

P A Windisch1, F J Papatheofanis, K A Matuszewski

  • 1Clinical Practice Advancement Center, University HealthSystem Consortium, Oak Brook, IL 60521, USA. windisch@msgate.uhc.edu

The Annals of Pharmacotherapy
|April 30, 1998
PubMed
Summary

Recombinant human growth hormone (rhGH) shows promise in treating AIDS-associated wasting by increasing lean body mass. However, more research is needed to confirm sustainable benefits and long-term outcomes for patients with HIV.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and economic outcomes of coronary angioplasty alone or in combination with stents in academic health centers: a retrospective database analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

Transfusion·2001
Same author

Can administrative database studies inform medication use policy decisions? An application of Occam's razor.

The American journal of managed care·2001
Same author

Using a multihospital systems framework to evaluate and establish drug use policy.

Journal of medical systems·2000
Same author

Health technology assessment.

The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)·2000
Same author

Utility evaluations for Markov states of lung cancer for PET-based disease management.

The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)·2000

Area of Science:

  • Endocrinology and Metabolism
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • AIDS-associated wasting is a significant metabolic complication of HIV infection, characterized by involuntary loss of body cell mass.
  • This condition leads to muscle weakness and organ failure, negatively impacting patient prognosis.
  • Understanding effective therapeutic interventions is crucial for managing HIV/AIDS patients.

Purpose of the Study:

  • To review the existing literature on the efficacy of recombinant human growth hormone (rhGH) for treating AIDS-associated wasting.
  • To compare rhGH therapy with alternative treatment options.

Main Methods:

  • A comprehensive literature search was conducted using MEDLINE and AIDSLINE databases from 1985 to 1997.
  • Inclusion criteria focused on English-language clinical trials and human studies specifically addressing AIDS-associated wasting.

Related Experiment Videos

  • Keywords included growth hormone, HIV, AIDS, wasting, and weight gain.

    • Main Results:

    • Recombinant human growth hormone (rhGH) is FDA-approved for treating AIDS-associated wasting.
    • rhGH administration (4-6 mg daily subcutaneously) increases lean body mass and decreases adipose tissue.
    • It presents a more costly alternative to appetite stimulants like megestrol acetate and dronabinol.

    Conclusions:

    • Clinical trials suggest rhGH is encouraging for managing wasting in AIDS patients, but long-term sustainable outcomes require further investigation.
    • The translation of increased lean body mass and decreased fat into reduced hospitalization, morbidity, and mortality remains undetermined.
    • A formal health economic assessment is necessary to evaluate the full impact of rhGH on the healthcare system.